E23DEBIRI and cetuximab (DEBIRITUX) as a secondline...

Annals of Oncology 2015 / 10 Vol. 26; Iss. suppl 6

E23DEBIRI and cetuximab (DEBIRITUX) as a secondline treatment for unresectable colorectal liver metastases (UCLM): results of a phase II trial exploring a new sequence

Fiorentini, G., Aliberti, C., Sarti, D., Coschiera, P., Tilli, M., Mulazzani, L., Giordani, P., Graziano, F., Marqués Gonzalez, A., García Marcos, R., Gómez Mugnoz, F., Cantore, M., Ricci, S., Catalan
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
26
Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdv340.23
Date:
October, 2015
File:
PDF, 34 KB
english, 2015
Conversion to is in progress
Conversion to is failed